Original Anti-PD1 checkpoint inhibitor with or without chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma

doi:10.1016/j.tranon.2020.100989

	Original Anti-PD1 checkpoint inhibitor with or without chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma
	Jin, Ting 1,2; Zhang, Qun 3; Jin, Qi-Feng 1,2; Hua, Yong-Hong 1,2; Chen, Xiao-Zhong 1,2
刊名	TRANSLATIONAL ONCOLOGY
	2021-02-01
卷号	14
关键词	Nasopharyngeal carcinoma Metastasis Chemotherapy Recurrence Anti-PD1 checkpoint inhibitor
ISSN号	1936-5233
DOI	10.1016/j.tranon.2020.100989
通讯作者	Chen, Xiao-Zhong(cxzfyun@sina.com)
英文摘要	Purpose: To compare the efficacy and safety of anti-PD1 checkpoint inhibitor plus chemotherapy with anti-PD1 checkpoint inhibitor alone in recurrent and metastatic nasopharyngeal carcinoma (R/M NPC) progressing after first or subsequent-line therapy. Methods and materials: A total of 67 patients with recurrent and metastatic nasopharyngeal carcinoma from our hospital were included. All patients were sorted into two arms: anti-PD1 checkpoint inhibitor + chemotherapy arm and anti-PD1 checkpoint inhibitor arm. We retrospectively estimated objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) in patients of both arms. Chi-square test and Kaplan- Meier methodology were used to analyze. Results: From September 2018 to March 2020, this research included 67 patients. For anti-PD1 checkpoint inhibitor + chemotherapy arm, partial response and stable disease were observed in fourteen and 11 patients, respectively, for an ORR of 53.8%. For anti-PD1 checkpoint inhibitor arm, complete response and partial response were observed in one and 5 patients, respectively, for an ORR of 14.6%. The incidence of hyperprogressive disease was higher in the anti-PD1 checkpoint inhibitor group compared with anti-PD1 checkpoint inhibitor + chemotherapy group (39.0% vs 3.8%, p < 0.05). Univariable analyses discovered that 6-month PFS and OS benefits were observed for anti-PD1 checkpoint inhibitor + chemotherapy arm compared to anti-PD1 checkpoint inhibitor arm (65.4% vs. 28.6%, P = 0.001; 100.0% vs. 73.5%, P = 0.014). Conclusion: In present study, we revealed that adding chemotherapy to anti-PD1 checkpoint inhibitor significantly improved 6-month PFS and OS for patients with R/M NPC progressing after first-line therapy. It warrants further study.
资助项目	Zhejiang Province Medical and Health Science and Technology Project[2021KY596] ; Zhejiang Province Medical and Health Science and Technology Project[2018KY315] ; National Natural Science Foundation of China[81672971] ; Excellent Talents Project of Zhejiang Cancer Hospital, P. R. China[2013]
WOS关键词	PHASE-II TRIAL ; CONCURRENT CHEMORADIOTHERAPY ; ANTITUMOR-ACTIVITY ; ASIAN PATIENTS ; MULTICENTER ; IFOSFAMIDE ; CISPLATIN ; COMBINATION ; GEMCITABINE ; PACLITAXEL
WOS研究方向	Oncology
语种	英语
出版者	ELSEVIER SCIENCE INC
WOS记录号	WOS:000729690900012
资助机构	Zhejiang Province Medical and Health Science and Technology Project ; National Natural Science Foundation of China ; Excellent Talents Project of Zhejiang Cancer Hospital, P. R. China
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/126912]
专题	中国科学院合肥物质科学研究院
通讯作者	Chen, Xiao-Zhong
作者单位	1.Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou 310000, Peoples R China 2.Chinese Acad Sci, Inst Canc & Basic Med IBMC, Hangzhou 310000, Peoples R China 3.Sun Yat Sen Univ, Affiliated Hosp 1, Dept Radiat Oncol, Guangzhou 510060, Peoples R China
推荐引用方式 GB/T 7714	Jin, Ting,Zhang, Qun,Jin, Qi-Feng,et al. Original Anti-PD1 checkpoint inhibitor with or without chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma[J]. TRANSLATIONAL ONCOLOGY,2021,14.
APA	Jin, Ting,Zhang, Qun,Jin, Qi-Feng,Hua, Yong-Hong,&Chen, Xiao-Zhong.(2021).Original Anti-PD1 checkpoint inhibitor with or without chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma.TRANSLATIONAL ONCOLOGY,14.
MLA	Jin, Ting,et al."Original Anti-PD1 checkpoint inhibitor with or without chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma".TRANSLATIONAL ONCOLOGY 14(2021).